Prof. Dr. rer. nat. Matthias Peipp
Facts
Phone:
+49-431-500-22769
E-Mail:
m.peipp@med2.uni-kiel.de
Affiliations:
Division of Antibody-based Immunotherapy / University Medical Center Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel
Address:
Rosalind-Franklin-Str. 12, 24105 Kiel
Curriculum vitae
Education/Training
12/1997-07/2003 | PhD thesis: molecular biology / immunology (graduation: Dr. rer. nat., with distinction) |
10/1991-08/1997 | Course of studies: biology (graduation: diploma, 1.3, very good) |
Research Experience/Academic Appointments
08/2015-07/2020 | Mildred-Scheel Professorship in antibody-based tumor immunotherapy (Division of stem cell transplantation and immunotherapy, Kiel) |
07/2012 | Habilitation (Division of stem cell transplantation and immunotherapy, Kiel) |
Since 08/2008 | Group leader position (Division of stem cell transplantation and immunotherapy, Kiel) |
04/2006-07/2008 | PostDoc (Division of stem cell transplantation and immunotherapy, Kiel) |
04/2004-03/2006 | PostDoc (Nephrology Department, University Hospital Schleswig-Holstein, Kiel) |
08/2003-03/2004 | PostDoc (Chair of genetics, Friedrich-Alexander-University Erlangen- Nuremberg) |
Important Scientific Prizes/Functions
2016 | Hensel-Preis by the Hensel Foundation (100.000 Euro support) |
2015 | Endowed Mildred-Scheel Professorship in antibody-based immunotherapy (1 Mio. Euro support) |
Project-related publications
P1, P3, P6, P7, Z
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis
P3, P4, P6, P7, Z
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
P3, P6, P7, Z
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
P7